Scholar Rock Holding Co. (NASDAQ:SRRK) CFO Edward H. Myles Sells 7,809 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) CFO Edward H. Myles sold 7,809 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the completion of the transaction, the chief financial officer now directly owns 140,740 shares of the company’s stock, valued at approximately $5,183,454.20. This trade represents a 5.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $39.15 on Friday. The firm has a fifty day moving average price of $41.89 and a two-hundred day moving average price of $28.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright raised their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial raised their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 price target on shares of Scholar Rock in a report on Wednesday, January 29th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and an average price target of $40.43.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after buying an additional 269 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Scholar Rock during the 4th quarter valued at $85,000. Finally, Amalgamated Bank raised its position in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.